💥Mains Ready By December. Smash Mains & Smash PYQ Admissions Open
Talk to Mentor

Civilsdaily

Login

Subject: Science and Technology

  • Typhoid control needs more vaccine, less antibiotic

    Typhoid control needs more vaccine, less antibiotic

    Why in the News

    Typhoid cases in India are mounting without attracting the attention that influenza and swine flu currently draw, and every suspected case becomes a trigger for inappropriate or unnecessarily broad-spectrum antibiotic use. The disease is bacterial and vaccine preventable, yet it continues to be diagnosed imperfectly and treated empirically. The reason is the absence of a simple, reliable and accessible diagnostic test, which leaves the clinician with suspicion rather than confirmation. The tension is that the same empirical prescribing that substitutes for a diagnosis also generates the antimicrobial resistance in Salmonella typhi that makes future typhoid harder to treat, and it destroys the case data needed to see that resistance building.

    What is the typhoid conjugate vaccine?

    1. What it is: The typhoid conjugate vaccine (TCV) links the Vi capsular sugar coat of Salmonella typhi to a carrier protein. The conjugation produces a durable immune response, including in children under two, which the older unconjugated vaccine did not.
    2. India’s manufacturing position: India produced the world’s first World Health Organization (WHO) prequalified typhoid conjugate vaccine, Typbar-TCV, in 2017. Additional Indian products have achieved WHO prequalification since then.
    3. Where WHO places it: The WHO has prioritised introduction of the vaccine in countries carrying a high typhoid burden or high levels of antimicrobial resistance.

    Why does typhoid get treated without being diagnosed?

    1. A single Widal test settles nothing: The Widal test measures antibodies against Salmonella typhi, and one result is not sufficient to establish a diagnosis of acute typhoid.
    2. Endemicity corrupts the reading: In an endemic country such as India, background antibodies and previous exposure or vaccination make the result difficult to interpret. In routine practice a positive Widal result may still be treated as confirmation.
    3. The laboratory standard is only half sensitive: Blood culture remains the conventional laboratory standard. The latest WHO typhoid guidance puts the sensitivity of a single blood culture at only around 55 to 60 per cent.
    4. What the yield depends on: Sensitivity is influenced by the volume of blood collected and, critically, by prior exposure to antimicrobials.
    5. The vicious cycle this creates: A patient develops prolonged fever and takes an antibiotic before seeking care. The blood culture drawn afterwards returns negative, and the clinician responds to unresolved suspicion by escalating or changing the antibiotic.

    What does empirical treatment cost beyond the individual patient?

    1. Every course adds selection pressure: India already faces increasing resistance in Salmonella typhi, and each unnecessary antibiotic course creates additional selection pressure on the organism.
    2. Every missed case blanks the record: A patient treated without microbiological confirmation never enters the resistance data, so the surveillance that should guide prescribing is undermined by the prescribing itself.
    3. Breadth compounds the damage: The response to diagnostic uncertainty is a broader spectrum agent, which acts on organisms far beyond the one suspected.

    Why is a vaccine preventable disease being fought with antibiotics?

    1. The capability is not the constraint: The scientific and manufacturing capability exists and the vaccine exists. What remains inadequate is the scale and the rigour of its use.
    2. India is the case WHO describes: India is one of the countries where the combination of disease burden and resistance makes the case for typhoid vaccination compelling.
    3. Vaccination does not displace the basics: It cannot be treated as a substitute for clean water, sanitation, food safety or better diagnostics. It has to be one component of an integrated typhoid control strategy.

    What would an integrated typhoid control strategy require?

    1. Surveillance triggered by the case rise: Reports of increasing typhoid should themselves trigger strengthened surveillance. Hospitals and laboratories should systematically document suspected and culture confirmed cases, antimicrobial susceptibility patterns and prior antibiotic exposure.
    2. Diagnostic stewardship inside antimicrobial stewardship: Blood cultures should ideally be obtained before antibiotics are started, with adequate blood volume and appropriate laboratory practices.
    3. A test that works at the point of care: India needs investment in a better point of care or rapid diagnostic test for typhoid.
    4. A settled place for the vaccine: The position of the typhoid conjugate vaccine in the public health strategy needs to be revisited rather than left to individual prescribing decisions.

    Challenges to scaling the typhoid conjugate vaccine

    1. It sits outside the routine immunisation schedule: The vaccine is not part of the Universal Immunisation Programme, so uptake depends on the private market and on paying households. Eg. Coverage is concentrated in urban private paediatric practice rather than in the dense settlements where typhoid transmission is highest. Fix. Introduce it in a phased manner in high burden urban districts first, with the introduction decision anchored to culture confirmed case data.
    2. The vaccine does not cover the whole disease: Enteric fever is also caused by Salmonella paratyphi A, against which the conjugate vaccine gives no protection. Eg. A vaccinated patient presenting with prolonged fever still requires the same diagnostic workup. Fix. Fund development of a bivalent conjugate covering both organisms alongside scale up of the existing product.
    3. Introduction cannot be measured without a denominator: Without culture confirmed case counts there is no baseline against which to judge whether the vaccine reduced disease. Eg. Resistance data in India is heavily skewed towards tertiary hospitals rather than the community. Fix. Make enteric fever notifiable with mandatory laboratory reporting so introduction and impact are both measurable.
    4. Catch-up campaigns are the expensive part: A single dose given from six months of age is cheap, and a mass campaign across older cohorts is not. Eg. The cold chain and session load of a campaign compete directly with routine immunisation days. Fix. Attach the catch-up to existing school health programmes rather than running a parallel delivery system.

    Conclusion

    India has the vaccine and the manufacturing base to use it widely. What it does not have is a count of who actually has typhoid, because most cases are treated on symptoms and never confirmed in a laboratory. That missing count is exactly what would tell the government where to vaccinate first and whether it worked. The marker to watch is whether the typhoid conjugate vaccine enters the Universal Immunisation Programme, or stays held up waiting on data the country has not begun collecting.

    What is Antimicrobial Resistance?

    1. About: Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites evolve and stop responding to medicines that once treated them. It is often termed the silent pandemic.
    2. The One Health scope: Human medicine, animal husbandry and the environment form one reservoir, since resistant organisms move between them through food, water and waste.

    Laws and Rules Governing Antimicrobial Resistance

    1. Drugs and Cosmetics Act, 1940: The parent statute regulating manufacture and sale of medicines in India.
    2. Schedule H1: Requires a prescription and a sale register for listed antibiotics and second line drugs.
    3. Ban on irrational fixed dose combinations: The government banned 156 irrational fixed dose combinations in 2024, several being antibiotic cocktails with no scientific basis.

    Government Initiatives for Antimicrobial Resistance

    1. National Action Plan on AMR 2.0 (2025 to 2029): Sets sectoral targets across human health, animal health and the environment.
    2. Red Line Campaign: Marks prescription-only antibiotic packs with a red vertical stripe for buyer identification.
    3. Indian Council of Medical Research (ICMR) AMR Surveillance Network: Collects susceptibility data from tertiary care hospitals.

    Key Facts about Antimicrobial Resistance

    1. Consumption pattern: 59 per cent of antibiotics consumed in India in 2022 were in the WHO Watch category, meant to be used sparingly.
    2. Animal use ranking: India is the fourth largest consumer of antibiotics for animals, with an 82 per cent rise projected by 2030.
    3. Newborn burden: More than 50,000 newborn deaths a year in India are attributed to resistant sepsis.

    Challenges in Antimicrobial Resistance

    1. Antibiotics still move over the counter: Retail enforcement of the prescription requirement is weak, so a course is bought like a painkiller. Eg. The pill popping habit widened after the COVID-19 pandemic, with antibiotics taken for viral illness. Fix. Make the Schedule H1 register a digital point of sale entry so it can be audited rather than inspected.
    2. Manufacturing effluent seeds resistance in rivers: Untreated effluent from drug production enters water bodies and selects for resistant organisms outside any clinic. Eg. The Musi river near Hyderabad shows antibiotic levels a thousand times above safe limits. Fix. Tie public procurement preference to plants certified for zero liquid discharge.
    3. Farm use is a growth strategy, not a treatment: Antibiotics are given routinely in poultry and aquaculture to accelerate weight gain, not to treat disease. Eg. Shrimp samples have shown up to 100 per cent ampicillin resistance. Fix. Subsidise animal vaccines and enforce farm to fork traceability so residue traces to a producer.

    Matching Previous Year Question

    “[2020] What is the importance of using Pneumococcal Conjugate Vaccines in India? (1) These vaccines are effective against pneumonia as well as meningitis and sepsis. (2) Dependence on antibiotics that are not effective against drug-resistant bacteria can be reduced. (3) These vaccines have no side effects and cause no allergic reactions. Select the correct answer using the code given below: (a) 1 only (b) 1 and 2 only (c) 1 and 3 only (d) 1, 2 and 3 ANSWER: (b)”

  • Govt. eases norms for defence exports, licences

    Why in the News

    The Defence Ministry has simplified its Defence Export Standard Operating Procedure (SOP) and overhauled the Open General Export Licence (OGEL) framework to help Indian defence manufacturers access global markets faster. Stakeholder consultation with concerned ministries and government agencies has been dispensed with for exports of non-lethal defence items to most destinations, though safeguards continue for sensitive countries, and the same consultation requirement has been removed altogether for exports linked to international tenders and exhibitions.

    What has changed under the revised Export SOP?

    1. Reduced consultation for non-lethal exports: Stakeholder consultation with concerned ministries and agencies is no longer required for exporting non-lethal defence items to most destinations, though safeguards remain in force for sensitive countries.
    2. No consultation for tenders and exhibitions: The same consultation requirement has been dropped for exports of all items meant for international tenders and exhibitions, letting Indian companies pursue overseas opportunities faster.

    How has the OGEL framework been restructured?

    1. Consolidated procedures: Three separate OGEL SOPs, covering major platforms and equipment, parts and components, and intra-company technology transfer, have been merged into a single framework.
    2. Longer validity and wider country coverage: OGEL validity has been extended from two years to three, and its country coverage expanded from 41 countries to all countries except those designated negative or sensitive.
    3. A new licence category for long-term contracts: Indian companies with long-term contracts or agreements with foreign original equipment manufacturers can now obtain an OGEL for eligible items tied to that specific manufacturer, with validity aligned to the underlying contract.
    4. Expanded item coverage: OGEL eligibility now extends to civil-end-use exports of specified small-calibre arms components and protective equipment.

    Challenges to the liberalised export and licensing regime

    1. Diversion risk from wider country coverage: Extending OGEL coverage to all countries except a negative list raises the risk that dual-use or sensitive items reach unintended end users through re-export or transhipment. Eg. Widened general licensing regimes elsewhere have previously required retrofitted end-use verification systems after initial liberalisation exposed gaps, as seen in tightened United States Commerce Control List enforcement following early Export Administration Regulations liberalisation. Fix. Pair the wider OGEL coverage with mandatory post-export end-use certification audits for a sample of shipments to non-treaty destinations.
    2. Consultation removal versus oversight continuity: Dispensing with stakeholder consultation for non-lethal exports speeds approvals but removes a cross-ministry check that previously caught destination-specific concerns before shipment. Eg. Non-lethal classification itself can be contested, since components with civil and military dual use, such as certain protective equipment, may be misclassified at the exporter’s discretion. Fix. Retain a post-facto sampling audit by the Department of Defence Production even where pre-export consultation is waived.

    Conclusion

    The Defence Ministry’s overhaul of the Export SOP and the OGEL framework liberalises licensing timelines, validity and country coverage for Indian defence exporters while explicitly retaining safeguards for sensitive countries and technologies. The stated intent is to let Indian manufacturers respond faster to international tenders and deepen co-production ties with foreign original equipment manufacturers.

    Back2Basics: What is an Open General Export Licence (OGEL)?

    1. An OGEL is a standing, one-time authorisation that lets an eligible exporter self-generate export authorisations for multiple consignments of specified defence items without seeking a separate approval for every individual shipment.
    2. It is administered by the Defence Ministry’s Department of Defence Production and covers major platforms and equipment, parts and components, and intra-company technology transfers.
    3. Its use remains subject to end-destination safeguards, so items bound for negative or sensitive countries continue to require case-by-case authorisation outside the OGEL route.

    Matching Previous Year Question

    No direct PYQ traced in the provided files.

  • Nuclear power operator plans new design unit to support pvt players

    Nuclear power operator plans new design unit to support pvt players

    Why in the News

    The Nuclear Power Corporation of India Limited (NPCIL) is setting up a new design vertical to support private companies deploying Pressurised Heavy Water Reactor (PHWR) technology. This follows recent legal reform enabling private participation in civil nuclear power. The move marks a shift from NPCIL’s traditional role as sole builder and operator of India’s nuclear fleet toward a design-support role for private entrants, addressing India’s stated need to scale nuclear capacity to meet rising electricity demand while keeping deployment within a technology NPCIL already operates at scale.

    Why does India favour PHWR technology for private entry?

    1. Established domestic supply chain: PHWR technology has been indigenised in India since the 1980s, giving it a mature domestic manufacturing and fuel-cycle base that a newly entering private player can draw on.
    2. Natural uranium fuel cycle: PHWRs use natural, unenriched uranium, avoiding dependence on enrichment technology that remains tightly controlled internationally.

    What does NPCIL’s new design unit change?

    1. From sole operator to technology enabler: NPCIL will now provide design support to private players rather than being the only entity that builds and runs reactors, opening a role private companies previously could not access.
    2. Institutional capacity test: Whether NPCIL’s new vertical can support multiple private projects simultaneously, without diverting engineering capacity from its own ongoing reactor construction, remains to be demonstrated.

    Pressurised Heavy Water Reactor (PHWR)

    • PHWR = Pressurised Heavy Water Reactor uses heavy water (deuterium oxide, D₂O) as moderator and Coolant
    • It uses natural, unenriched uranium as fuel.

    Key Features of PHWR

    Heavy Water

    • Heavy water contains deuterium, an isotope of hydrogen.
    • It acts as both the moderator and coolant in PHWRs.

    Natural Uranium

    • PHWRs can operate using natural uranium, avoiding the need for uranium enrichment for the reactor fuel.

    Online Refuelling

    • PHWRs permit online refuelling.
    • Fuel bundles can be replaced while the reactor continues operating.
    • Therefore, the reactor does not need to be shut down for routine fuel replacement.

    “[2017, GS3, 15 marks] Give an account of the growth and development of nuclear science and technology in India. What is the advantage of fast breeder reactor programme in India?”

    [2023] Consider the following statements:
    Statement-IIndia, despite having Uranium deposits, depends on coal for most of its electricity production.
    Statement-II:Uranium, enriched to the extent of at least 60%, is required for the production of electricity.
    Which one of the following is correct in respect of the above statements

    [A] Both Statement-I and Statement – II are correct and Statement- II is the correct explanation for Statement- I

    [B] Both Statement I and Statement II are correct and Statement-II is not the correct explanation for Statement-I.

    [C] Statement- I is Correct but Statement-II is incorrect.

    [D] Statement-I incorrect but Statement-II is correct.

  • Rajnath approves transfer of missile technology to domestic defence industry

    Rajnath approves transfer of missile technology to domestic defence industry

    Why in the News

    Defence Minister Rajnath Singh has approved the transfer of technology (ToT) for all conventional missile systems developed by the Defence Research and Development Organisation (DRDO) to the Indian defence industry, opening the way for domestic private production of these systems for the first time. Until now, production had rested with Defence PSU Bharat Dynamics Limited, DRDO’s own in-house facilities, and the India-Russia joint venture that builds the BrahMos cruise missile. This is a One development, one row item; both The Hindu and The Indian Express carried the decision, and this entry is filed from the Indian Express account, which names the specific missile systems and the strategic systems excluded from transfer.

    What does the transfer of technology actually change?

    1. A closed production model opens to private industry: Production of DRDO-developed conventional missile systems was previously confined to a defence PSU and DRDO’s own facilities; the ToT decision allows private companies, MSMEs, and other technology partners to manufacture these systems, subject to qualifications, certifications, and regulatory requirements.
    2. An initial set of named systems anchors the rollout: Officials cited the beyond-visual-range air-to-air missile ASTRA, the anti-radiation missile RUDRAM, the short-range air defence system VSHORADS, the anti-tank guided missile NAG, and the Naval Anti-Ship Missile (NASM) as the systems the initiative could begin with, though the stated goal is to extend private production to all conventional missile systems.
    3. Strategic systems are explicitly carved out: The Agni series and the K-series missiles will not be part of this technology transfer, since they are classified as strategic missiles rather than conventional ones.
    4. The stated objective is industrial-scale transition: The Ministry of Defence framed the decision as enabling the transition of missile projects from the development stage to industrial-scale production, reducing import dependence and increasing indigenous value addition.

    Conclusion

    The decision restructures who is permitted to manufacture India’s conventional missile systems, shifting DRDO’s role from developer-cum-producer to developer-cum-technology-provider, and is intended to widen the industrial base, including private firms and MSMEs, that can supply the country’s expanding conventional missile requirements.

  • Opposition raises concerns over ‘weakening’ of ISRO; Centre hits back

    Why in the News

    Opposition parties in Parliament questioned the government’s push to privatise parts of the space sector, citing recent resignations at the Indian Space Research Organisation (ISRO) and asking whether the shift toward private participation is weakening the organisation. The government responded by citing the $44-billion space economy target, the Kulasekarapattinam spaceport under development, and continued investment in the Sriharikota launch facility, arguing that private participation is expanding, not displacing, ISRO’s role.

    What is the Opposition’s specific concern?

    1. Reported resignations at ISRO cited as evidence of institutional strain: Opposition members pointed to recent resignations at ISRO as a sign that the organisation is losing talent, and linked this to the government’s parallel push to open the space sector to private companies.
    2. Question framed as public-versus-private capacity, not merely personnel: The core question raised was whether directing new space-sector opportunities toward private players comes at the cost of ISRO’s own institutional capacity and morale, rather than being framed as a narrow human-resources issue alone.

    How did the government respond?

    1. The $44-billion space economy target as the framing device: The government’s rebuttal centred on India’s targeted space economy size, cited at $44 billion, arguing that reaching this scale requires private capacity in addition to, not instead of, ISRO’s own programmes.
    2. The Kulasekarapattinam spaceport as evidence of expansion: The government cited the Kulasekarapattinam spaceport, under development in Tamil Nadu specifically to support the small-satellite launch vehicles that private and ISRO missions alike are expected to use, as evidence of continuing public investment in launch infrastructure.
    3. Continued investment in Sriharikota: The government also pointed to ongoing investment in the Sriharikota launch facility, ISRO’s principal spaceport, as evidence that ISRO’s core launch infrastructure is being expanded rather than run down.

    What is the structural relationship between ISRO and India’s growing private space sector?

    1. IN-SPACe as the facilitating body for private entry: The Indian National Space Promotion and Authorisation Centre (IN-SPACe), an autonomous body under the Department of Space, was created specifically to authorise and facilitate private-sector participation in space activities that were previously the exclusive domain of ISRO.
    2. NewSpace India Limited as the commercial arm: NewSpace India Limited, the public sector undertaking under the Department of Space, commercialises ISRO-developed technology and manages the transfer of ISRO capabilities to industry.
    3. Private launch capability is still at an early, unproven stage: Private Indian space companies have made progress, including new propulsion technologies, but have not yet demonstrated launch capability at the scale or reliability of ISRO’s own vehicles, meaning private participation currently supplements rather than substitutes for ISRO’s launch role.

    Conclusion

    The exchange reflects a genuine disagreement over sequencing rather than over the direction of India’s space policy: both sides accept that private participation is expanding, and the dispute is over whether that expansion is currently coming at ISRO’s institutional expense. Whether the resignations flagged by the Opposition reflect a broader retention problem, or are within the range any large scientific organisation experiences, will only be clear from data the government has yet to place before Parliament.

    Back2Basics: Indian National Space Promotion and Authorisation Centre (IN-SPACe)

    1. An autonomous, single-window agency under the Department of Space, established to authorise, promote, and regulate private-sector space activities in India.
    2. Created as part of the 2020 space-sector reforms that opened satellite building, launch vehicle development, and space-based services to private Indian companies.
    3. Functions separately from ISRO, which retains its own research, development, and launch mandate, so the two operate as parallel rather than competing structures.
    4. Reviews and clears private-sector proposals for satellite launches, ground infrastructure, and related space activities.

    Matching Previous Year Question

    “[2026] Consider the following statements about involvement of private entities in India’s space programme:
    1. IN-SPACe is an autonomous agency formed to facilitate participation of private entities.
    2. Agnikul Cosmos launched the world’s first flight using 3D-printed rocket engine.
    3. Skyroot Aerospace has developed liquid fuel for GSLV.
    (a) 1 only
    (b) 2 and 3 only
    (c) 1 and 2 only
    (d) 1, 2 and 3
    ANSWER: C”

  • The personalised vaccine that could cut skin cancer death risk

    The personalised vaccine that could cut skin cancer death risk

    Why in the News

    A new personalised cancer vaccine, intismeran, administered alongside the immunotherapy drug Keytruda, has been shown in Phase 3 results to reduce the risk of death from the recurrence and spread of skin cancer.

    How does intismeran work?

    1. Step one, read the tumour: The therapy begins by identifying the mutations, called neoantigens, in a sample of the patient’s own tumour.
    2. Step two, build the instruction set: A vaccine is then made of synthetically developed messenger RNA (mRNA), a single stranded molecule that carries genetic instructions from DNA in the cell nucleus and tells the cell which proteins to make. Each treatment consists of mRNA coding for 34 such neoantigens.
    3. Step three, administer and translate: Once administered, the body generates these proteins from the mRNA instructions.
    4. Step four, present to the immune system: The body then presents those proteins to the immune system, which is trained to recognise them as belonging to the cancer.

    Why must a cancer vaccine be personalised?

    1. Neoantigens exist only on cancer cells: Neoantigens are proteins found only on the cancerous cells, which the body’s immune system can be trained to recognise.
    2. They differ from patient to patient: These neoantigens vary from person to person, so they become an identifier for that individual’s cancer and cannot be mass produced as a single formulation.
    3. The principle is the same as any vaccine: A vaccine for an infectious disease contains the antigen from a pathogen, the proteins or lipids that train the immune system to recognise and fight it, and this therapy contains cancer neoantigens instead.
    4. The benefit is immunological memory: The cancer’s fingerprint enters the immune system’s memory, so if the cancer returns the body can recognise it immediately and mount a response, prolonging recurrence free survival.
    5. A decade of work behind one result: Work on this approach has run for around a decade, and this is the first clinical breakthrough.

    What did the Phase 3 study find?

    1. Death risk from recurrence fell: When the vaccine was given with Keytruda, the risk of death owing to recurrence of skin cancer went down by 49 per cent.
    2. Death risk from spread fell further: The risk of death owing to the cancer spreading went down by 59 per cent.
    3. The comparison arm matters: Both results are measured against treatment with Keytruda alone, not against no treatment.
    4. The comparison arm is already strong: Keytruda (pembrolizumab, a checkpoint inhibitor that blocks the PD-1 receptor cancer cells use to switch off the immune response against them) has over the years been shown to be much more effective in treating certain cancers than traditional chemotherapy, so the gain sits on top of an established benchmark.
    5. Side effects were mild: The most common side effects noted in the study were fatigue, injection site pain and chills.

    What does this mean for India?

    1. Reason one, the disease is rare here: Melanoma is one of the most common types of cancer in the caucasian population, and is not commonly seen among Indians.
    2. The share is a fraction of a per cent: Globocan, short for Global Cancer Observatory, an online platform that maintains cancer statistics, shows that melanoma accounts for only 0.26 per cent of all cancer cases in India and 0.17 per cent of deaths.
    3. Reason two, cost: Most patients in India are unable to afford Keytruda even with patient assistance programmes, and a combination therapy compounds a barrier that already exists for the immunotherapy alone.
    4. Access to immunotherapy is already narrow: A real world study from Tata Memorial Hospital showed that only 1.6 per cent of the patients who need such immunotherapy are able to access it.

    Challenges to personalised mRNA cancer vaccines

    1. Every dose is a separate manufacturing run: The vaccine must be sequenced, designed and produced per patient, so the process cannot be batched and the turnaround competes with tumour progression. Eg. Each treatment encodes 34 neoantigens specific to one person’s tumour. Fix. Build automated, closed-system manufacturing units co-located with cancer centres, on the model already used for cell therapy production.
    2. Cost scales with individualisation: A therapy that cannot be mass produced carries no volume discount, so the price gap over a standard drug widens rather than narrows with adoption. Eg. Even the standard companion immunotherapy reaches only 1.6 per cent of Indian patients who need it. Fix. Negotiate outcome linked pricing, where payment is tied to recurrence free survival achieved rather than to doses supplied.
    3. Cold chain requirements restrict reach: mRNA products require ultra-low temperature storage and transport, which most Indian district level oncology facilities do not have. Eg. Covid-19 mRNA vaccines were never widely deployed in India partly for this reason. Fix. Extend the cold chain built for the universal immunisation programme with ultra-low temperature capacity at regional cancer centres before such therapies are introduced.
    4. Tumours can escape the target: Cancer cells can lose the targeted antigen over time, which is the known failure mode of antigen directed immunotherapy. Eg. Relapse through antigen escape is documented in CAR-T cell therapy for blood cancers. Fix. Design vaccines against multiple conserved neoantigens and pair them with checkpoint inhibitors, so escape from one target does not end the response.
    5. Regulatory pathways assume a fixed product: Approval systems are built to assess an identical formulation across a trial population, while each dose here differs by design. Eg. India’s biotechnology approvals are already split across the Department of Biotechnology, the drug regulator and the environment ministry. Fix. Create a platform approval route that licenses the manufacturing process and the design algorithm rather than each individual product.
    6. The evidence is disease specific: The result is established for melanoma alone, and benefit in the cancers that dominate India’s burden is not demonstrated. Eg. Melanoma is 0.26 per cent of Indian cancer cases while breast, oral and cervical cancers account for the bulk. Fix. Prioritise Indian participation in trials of the same platform for oral, breast and cervical cancers, so approval evidence is generated on the local disease profile.

    Conclusion

    A personalised mRNA vaccine has for the first time produced a meaningful clinical benefit in cancer, cutting the risk of death from recurrence by 49 per cent and from spread by 59 per cent when added to an existing immunotherapy. The result validates the principle that a therapy can be built against each patient’s own tumour mutations rather than against a disease in general. For India the immediate impact is limited, because melanoma is rare here and the companion drug reaches under two per cent of the patients who need it. The question that remains open is whether the platform is extended to the cancers that actually dominate India’s disease burden.

    “[2022, GS3, 15 marks] What is the basic principle behind vaccine development? How do vaccines work? What approaches were adopted by the Indian vaccine manufacturers to produce COVID-19 vaccines?”

  • What India can learn from EU’s AI reset

    What India can learn from EU’s AI reset

    Why in the News

    The European Union’s Artificial Intelligence (AI) Omnibus entered into force on 27 July 2026 and changes parts of the European Union Artificial Intelligence Act, 2024 (EU AI Act). It extends some deadlines, simplifies some compliance requirements and gives regulators and companies more time to prepare for the high-risk AI rules.

    What is the EU AI Act’s risk-based framework?

    1. The organising principle: The Act sorts AI systems by the level of risk they pose and attaches obligations to each tier. The regulatory burden rises with the potential for harm rather than with the technology used.
    2. The prohibited tier: Some AI practices are prohibited outright under the Act. No compliance route is available for a practice in this category.
    3. The high-risk tier: High-risk systems face strict obligations before and during deployment. These are the obligations whose preparation deadlines the Omnibus has extended.
    4. General-purpose models: General-purpose AI models, meaning models trained broadly and adaptable to many downstream tasks rather than built for one application, came under a specific set of rules. They are governed separately from the risk tiers that apply to particular deployments.

    What does the AI Omnibus change, and why now?

    1. The instrument and its date: The AI Omnibus entered into force on 27 July 2026. It amends parts of the AI Act rather than replacing the framework.
    2. Deadlines extended: Some compliance deadlines under the Act have been pushed back. Regulators and companies have more time to prepare for the high-risk AI rules.
    3. Compliance simplified: Some compliance requirements have been simplified. The obligations themselves remain in place at their existing levels.
    4. The reason stated: Implementation of the original framework proved difficult in practice. The Omnibus is the EU’s response to that implementation experience rather than to a change in the risk assessment.
    5. How it is characterised: The change is an admission that AI is changing faster than laws can normally change. It demonstrates that even a carefully designed regulation must be capable of adjustment.

    What are the five lessons for India?

    1. Regulation must be capable of learning: Technology changes and risks change, so regulators must have the ability to review and adjust rules. Regulation should be treated as a continuing process rather than a single enactment.
    2. Regulation needs an escape valve: Rules work only where regulators and companies have the capacity to implement them. India should consider regulatory sandboxes and regular reviews of AI rules, and sunset mechanisms could make regulation more responsive.
    3. Compliance cost decides who can compete: Large technology companies can hire lawyers, engineers and auditors, and start-ups cannot always do so. Excessive compliance costs could unintentionally favour large companies and reduce competition.
    4. Simplification must not mean deregulation: Reducing paperwork is different from reducing safeguards. AI can create serious risks involving privacy, discrimination, manipulation and opaque decision-making, and simpler regulation must not mean weaker protection.
    5. Institutional maturity is the fifth lesson: The EU has shown that even a major regulatory framework can be revised after enactment. Regulatory maturity means recognising when rules are not working and changing them.

    Where does India’s AI governance currently stand?

    1. A different path so far: India has focused on responsible AI, innovation and sector-specific governance rather than creating a comprehensive AI law. Sectoral regulators apply existing mandates to AI within their own domains.
    2. Flexibility carries a cost: Flexibility can be useful and it should not become uncertainty. Businesses need clarity, citizens need protection and regulators need clear responsibilities.
    3. The proportionality principle India would need: The regulatory burden should depend on potential harm. The greater the risk to people and society, the stronger the safeguards should be.
    4. The assets India brings: India has a large digital population and experience with digital public infrastructure. It also has a growing technology sector and experience in deploying digital services at scale.
    5. The institutions available to build on: The IndiaAI Mission can play an important role in an adaptive Indian model of AI governance. Regulatory sandboxes, sectoral regulators, research institutions and industry bodies can carry the rest.

    Is regulation genuinely a trade-off against innovation?

    1. The framing the debate defaults to: The debate over AI is often presented as a choice between regulation and innovation. That framing treats every safeguard as a cost to be traded away.
    2. Why the framing is wrong: The choice is false because unregulated deployment carries its own costs in privacy, discrimination and opaque decision-making. The challenge is to design regulation that makes innovation safer and more trusted.
    3. What the EU revision actually demonstrates: The EU relaxed timelines and paperwork and did not relax the substantive safeguards. The revision therefore tests the trade-off framing and does not confirm it.
    4. The asymmetry the framing hides: Compliance cost falls hardest on the smallest firms, so heavy regulation reduces competition and light regulation reduces protection. India must create a framework that protects citizens while allowing experimentation, and be capable of changing as technology changes.

    Challenges to a risk-based AI law in India

    1. Risk tiers age faster than statutes: A fixed list of prohibited and high-risk uses is overtaken by capabilities that did not exist when the list was drawn. Eg. General-purpose models required a separate rule set in the EU Act after the original risk-tier design was settled. Fix. Place the risk classification in delegated rules subject to a mandatory periodic review rather than in the parent statute.
    2. Regulatory capacity is the binding constraint: Enforcement requires auditors and technical staff who can inspect model behaviour, and those skills are scarce in the public sector. Eg. Implementation difficulty is the stated reason the EU extended its own high-risk deadlines. Fix. Build a shared technical audit facility under the IndiaAI Safety Institute that sectoral regulators can draw on.
    3. Algorithmic bias reproduces existing exclusion: Models trained on historical data encode the patterns of that data, including patterns of discrimination. Eg. An automated recruitment system built at Amazon was found to downgrade applications from women. Fix. Mandate pre-deployment bias testing and published audit results for any system used in employment, credit or welfare decisions.
    4. The accountability gap in automated decisions: It is often unclear who is answerable for an AI-driven decision, the developer, the deployer or the administrator. Eg. A welfare eligibility system can deny a benefit without producing a reason the applicant can contest. Fix. Impose a statutory right to an explanation and to human review for any automated decision affecting a legal right or entitlement.
    5. Compute and data concentration: AI capability is concentrated in a few advanced economies, which leaves other countries as consumers rather than creators of the technology. Eg. India’s response has been a national compute grid of over 38,000 graphics processing units under the IndiaAI Mission. Fix. Treat compute, datasets and models as shared developmental resources with subsidised access for start-ups and researchers.

    Conclusion

    The EU has demonstrated that a comprehensive AI framework can be enacted and then revised when implementation shows it is not working, and the AI Omnibus of 27 July 2026 is that revision. Its lesson for India is not that regulation should be lighter but that it should be capable of learning, proportionate to harm, affordable for small firms and explicitly separate from deregulation. India has no comprehensive AI law and has the digital public infrastructure, the sectoral regulators and the IndiaAI Mission to build an adaptive one. What remains unresolved is whether India converts its current flexibility into a stated framework with clear responsibilities, or leaves it as uncertainty that businesses and citizens both bear.

    Government Initiatives on Artificial Intelligence

    1. IndiaAI Mission, 2024: Approved with an outlay of ₹10,371 crore and implemented by IndiaAI under the Ministry of Electronics and Information Technology. Its stated vision is making AI in India and making AI work for India, delivered through seven pillars.
    2. IndiaAI Compute and AIKosh: The compute pillar operates a national AI compute grid with over 38,000 graphics processing units at up to 40 per cent lower cost for eligible users. AIKosh is the national dataset repository with over 3,000 datasets and 243 models across 20 sectors.
    3. IndiaAI Foundation Models and FutureSkills: The foundation models pillar supports indigenous multimodal models built by entities including Sarvam AI and Gnani AI. FutureSkills funds fellowships and AI labs with a focus on Tier-2 and Tier-3 cities.
    4. Safe and Trusted AI: This pillar covers bias mitigation, privacy, explainability and AI governance, and it established the IndiaAI Safety Institute as a national trust framework. NITI Aayog’s Responsible AI for All initiative runs alongside it on public discourse and ethical audits.
    5. Language and access platforms: Digital India Bhashini provides speech and translation tools across 22 Indian languages, and Project Vaani has assembled a 150,000 hour Indian speech dataset. India hosted the India AI Impact Summit 2026 at Bharat Mandapam, the first major global AI summit in the Global South.

    “[2026] Which of the following statements with regard to Large Language Models (LLMs) used in machine learning is/are correct?

    1. LLMs assign probabilities to the next possible words and then pick the one with the highest probability.

    2. LLMs process data through mathematical optimization to minimise prediction errors.

    3. LLMs produce unbiased outputs.

    (a) 1 only

    (b) 1 and 2 only

    (c) 2 and 3 only

    (d) 1, 2 and 3

  • What changes when AI moves from reading viral genomes to designing them?

    Why in the News

    Researchers at Stanford University and the Arc Institute used Artificial Intelligence (AI) to design complete genomes of bacteriophages, viruses that infect bacteria. Of 285 AI-generated designs physically synthesised and tested in the laboratory, 16 produced functioning phages, and some overcame bacterial resistance that had defeated the original virus. Humans have been synthesising viral genomes and deliberately modifying viruses for decades, so what is new is not the physical manufacture of a virus. AI has entered the design stage of biology, deciding what the genome should be rather than executing a design a human specified. The tension is that the same capability that could transform antimicrobial resistance research, vaccines and therapeutics could also accelerate harmful biological engineering.

    What is a genome language model?

    1. What it is: A genome language model is a machine learning system trained on genetic sequence data rather than on text, and the two used in this experiment were Evo 1 and Evo 2.
    2. How it works: The principle resembles a large language model, except that instead of learning patterns in words, it learns patterns in DNA.
    3. What it reads: It studies the genetic alphabet of A, C, G and T across vast numbers of genomes, and then generates new genetic sequences from the patterns it has learned.
    4. How it was specialised: For this experiment the models were further trained on thousands of bacteriophage genomes related to ΦX174, so the sequences they generated stayed within a known biological family.

    What did the Stanford-Arc experiment actually do?

    1. The design step was handed over: The scientists already knew the ΦX174 genome and already knew how to synthesise viral DNA and recover functioning phages. What changed was who, or what, proposed the genome.
    2. The output was constrained, not open-ended: AI did not invent a completely unrelated virus from nothing. It generated previously unseen ΦX174-like whole genomes within a known biological framework.
    3. The build step was conventional: Scientists selected some of these sequences, physically manufactured the DNA and introduced it into E. coli. Where the genetic instructions were biologically coherent, the bacterial machinery produced new phage particles.
    4. The yield: Of the 285 designs tested, 16 succeeded in producing functioning phages.
    5. Some designs beat the natural virus: Combinations of AI-designed phages overcame resistance in E. coli strains against which the original ΦX174 failed.
    6. The most significant result was combinatorial: An AI-designed phage successfully combined a viral protein with other genetic changes in a way conventional engineering had struggled to achieve, which suggests the system can identify multiple genetic changes that work together across an entire genome.

    How did biology get from reading genomes to writing them?

    1. Phages are old and abundant: Bacteriophages, literally “bacteria eaters”, have been known for more than a century and are among the most abundant biological entities in nature.
    2. Reading came first: In 1977, one particularly small phage, ΦX174, became the first complete DNA genome to be sequenced.
    3. Writing came next: By the early 2000s, scientists had shown that viral genetic material could be synthesised from known sequence information and used to recover functioning viruses.
    4. Deliberate modification followed: The controversial influenza gain-of-function experiments of 2011-12 showed that genetic changes could modify important properties such as transmission in experimental animals.
    5. The unresolved dilemma: That research highlighted a dilemma that remains open, since the same science that can improve pandemic preparedness may also create biosafety and biosecurity risks.
    6. Design is the fourth step: The progression runs from reading viral genomes, to writing them, to modifying them, and now to AI helping decide what should be written.

    What does this open up in medicine?

    1. Phage therapy is the nearest application: Antibiotic resistance is steadily eroding conventional treatment options, and bacteriophages offer another way of killing bacteria.
    2. Specificity is the limitation: A phage effective against one bacterial strain may fail against another, and bacteria can also develop resistance to phages.
    3. The search model has limits: Researchers have traditionally searched nature and phage libraries for suitable candidates, or modified existing viruses, which caps the available options at what already exists.
    4. The question changes: Generative biology moves medicine from asking whether the needed phage can be found to asking whether it can be designed.
    5. The applications extend well beyond phages: AI can assist the design of vaccine antigens, antibodies, therapeutic proteins and the viral vectors used to deliver genetic treatments, and may eventually help optimise oncolytic viruses that selectively attack cancer cells.
    6. The real shift is broader than viruses: The larger revolution is AI becoming capable of designing biological function, rather than AI making viruses.

    Is the simplicity of the target a safeguard, or is the risk the acceleration?

    1. The reassuring reading: ΦX174 is an exceptionally simple bacteriophage, while dangerous human viruses are vastly more complicated.
    2. Human pathogens are harder targets: They must negotiate receptor binding, host range, tissue tropism, replication, immune escape and transmission, each of which is a separate design problem.
    3. Complexity is not a defence: Human scientists already understand much about these determinants, and decades of virology, reverse genetics and gain-of-function research have linked many genetic changes to viral behaviour.
    4. AI does not need to rediscover virology: Its power lies in integrating what humanity already knows, examining vastly more combinations than humans can explore manually, and accelerating the path from hypothesis to experimental design.
    5. The concern is capability amplification: The relevant question is not whether an untrained individual can ask today’s chatbot to generate a pandemic virus. It is whether increasingly capable AI could make a knowledgeable and well-equipped laboratory substantially more effective at designing biological systems.
    6. A low success rate is a temporary comfort: The yield reported above is low, but digital systems can generate enormous numbers of candidates, so a low success rate is reassuring only while the number of attempts remains small.

    How must biosecurity change?

    1. Current screening looks for resemblance: Traditional DNA-synthesis screening often asks whether an ordered sequence resembles a known pathogen or toxin.
    2. Resemblance fails against generated sequences: A previously unseen sequence generated inside a known family may not resemble anything on a watchlist while still doing the same thing.
    3. Screening must move to function: In the age of generative biology, screening must also consider what a sequence might actually do, not simply whether it looks dangerous.
    4. Over-restriction has its own cost: Claude Fable 5 was initially deployed with strong safeguards around biology, chemistry and cybersecurity, and legitimate scientific work could sometimes trigger a fallback to a less capable model.
    5. The correction points to graduated access: Those safeguards have since been refined to reduce false-positive biology fallbacks while more sensitive capabilities remain restricted, which points toward graduated, auditable access under institutional and security controls.
    6. Model refusal is not a strategy: Biosecurity cannot rest entirely on what an AI model agrees or refuses to answer, so safeguards are needed throughout the chain: AI systems, DNA-synthesis providers, laboratories and institutional biosafety oversight.

    Why does this matter for India?

    1. Frontier AI becomes scientific infrastructure: If frontier AI becomes central to drug discovery, genomics, vaccines, protein engineering and experimental design, access to advanced AI becomes part of national scientific infrastructure.
    2. Sufficiency and compulsion are different things: Smaller and specialised models will be sufficient for many tasks, but a country should choose a small model because it is sufficient, not be forced to use one because somebody else owns the frontier.
    3. Restricted access compounds over time: If researchers elsewhere receive trusted access to highly capable biomedical models while Indian scientists depend on restricted public versions, the disadvantage accumulates across drug discovery, vaccines and antimicrobial resistance.
    4. The investment exists but needs a scientific arm: India is already investing through the IndiaAI Mission and indigenous foundation-model programmes, and that ambition should extend to scientific and biomedical AI, secure compute and high-quality datasets.
    5. Trusted access needs a framework: Legitimate researchers need a defined route to stronger capabilities, which requires an institutional trusted-access framework rather than case by case negotiation with model providers.
    6. The two goals are not separable: AI sovereignty without biosecurity would be reckless, and biosecurity without AI sovereignty could leave the country scientifically dependent.

    Challenges to AI-designed genomes

    1. Sequence screening cannot see intent: Order screening matches against known pathogen sequences, so a generated sequence within a benign-looking family passes even where its function is hazardous. Eg. Screening protocols built around named agents on an export control list match those names, so a functionally equivalent sequence outside the list is not flagged. Fix. Require DNA-synthesis providers to run function prediction alongside sequence matching, with a reporting duty on flagged orders.
    2. Automated laboratories compress the safety window: Combining generative design with robotic experimentation shortens the interval in which oversight can intervene. Eg. Future systems may compress months or years of literature review, modelling and experimental planning into much shorter cycles. Fix. Mandate institutional biosafety committee sign-off at the design stage rather than only before physical synthesis.
    3. Volume defeats low success rates: A weak per-attempt success rate becomes a strong aggregate capability once attempts are cheap and unlimited. Eg. The design pool in this experiment was generated computationally, so the number of candidates was bounded by compute rather than by laboratory effort. Fix. Impose volume-based reporting thresholds on synthesis orders from a single requester within a stated period.
    4. Model safeguards obstruct legitimate research: Blunt refusal policies block the research they were meant to protect, which pushes scientists toward unsupervised alternatives. Eg. Legitimate scientific queries triggered fallback to a less capable model under initial biology safeguards. Fix. Operate tiered credentials, where verified institutional researchers receive higher-capability access under audit logging.
    5. Governance is nationally fragmented: Biosecurity rules stop at borders while synthesis orders and model access do not. Eg. The 2011-12 gain-of-function controversy produced divergent national moratoria rather than a common standard. Fix. Negotiate a common minimum synthesis-screening standard through the Biological Weapons Convention review process.
    6. India lacks a biosecurity institution for generative biology: Existing oversight bodies were designed for genetically modified organisms and field trials, not for computational design of pathogens. Eg. The Genetic Engineering Appraisal Committee and the Review Committee on Genetic Manipulation are structured around organism release rather than sequence design. Fix. Create a statutory biosecurity review function covering generative design, synthesis orders and model access, reporting jointly to the Department of Biotechnology and the Ministry of Electronics and Information Technology.

    Conclusion

    The experiment does not show that AI can casually manufacture dangerous human viruses. It shows something more precise: computers are beginning to move from analysing biological information towards proposing biological designs that scientists can physically build, a capability that serves therapeutic research and harmful engineering alike. The answer is neither prohibition nor unrestricted access, but controlled acceleration, with safeguards rising as capability and risk rise. The unresolved question is no longer whether AI should be allowed to understand biology, but how to govern it once understanding biology becomes the ability to design it.

    Back2Basics: IndiaAI Mission

    1. What it is: The IndiaAI Mission is the national artificial intelligence programme approved in 2024 with an outlay of ₹10,371 crore, implemented by IndiaAI under the Ministry of Electronics and Information Technology.
    2. Its stated vision: “Making AI in India and Making AI Work for India”, built around seven pillars covering compute, applications, datasets, foundation models, skills, startup financing and safe and trusted AI.
    3. Compute pillar: It operates a national AI compute grid with over 38,000 graphics processing units, offering up to 40 per cent lower compute costs to eligible users.
    4. Safety arm: The IndiaAI Safety Institute is its national trust framework, covering bias mitigation, privacy, explainability and AI governance.

    Matching Previous Year Question

    “[2026] Which of the following statements with regard to genetic medicine is/are correct? 1. Genetic medicines correct/compensate for the faulty genes responsible for disease. 2. Engineered viruses and lipid nanoparticles are used as carriers of the genetic medicine. 3. Genetic medicines alter the entire DNA sequence. (a) 1 only (b) 2 and 3 only (c) 1 and 2 only (d) 1, 2 and 3 ANSWER: C”

  • Global space norms find a firm footing in India’s new re-entry rules

    Global space norms find a firm footing in India’s new re-entry rules

    Why in the News

    The Indian National Space Promotion and Authorisation Centre (IN-SPACe) has released India’s first guidelines on planned re-entry, requiring any Indian entity undertaking such a re-entry to obtain its authorisation, whether the re-entry occurs within or outside Indian territory.

    What is a planned re-entry?

    1. The defining test is intent and survivability: Objects designed to survive re-entry, or intentionally controlled towards a particular landing or impact area, require separate authorisation. This is what makes a re-entry planned.
    2. What falls outside the definition: Objects expected to burn up, melt or fragment sufficiently during natural orbital decay do not count as a planned re-entry.
    3. Why the distinction carries regulatory weight: The category separates a return that must be assessed and cleared in advance from one that requires no clearance, so the definition determines the reach of the entire framework.

    Why has re-entry become a governance problem now?

    1. The historical baseline was negligible: For many decades there were few rocket launches and few new satellites in orbit each year, so there were also few re-entries.
    2. The consequences used to be trivial: Most of those re-entries simply burned up in the atmosphere with little consequence.
    3. The orbital population has changed: Low-earth orbit, the band of orbits closest to the earth where most satellites operate, now hosts several thousand satellites, with private companies planning for many more.
    4. Deliberate de-orbiting has become routine: Satellite operators are also deliberately bringing satellites down at the end of their operational lives as part of post-mission disposal, in great numbers.
    5. The physical risks are specific: A spacecraft returning to the earth has to negotiate many risks, including deviating from its planned path and breaking up into smaller pieces.
    6. The risks cross jurisdictions: A returning object may affect airspace and maritime zones, and may potentially crash in the territory or jurisdiction of another state, which makes re-entry a governance problem as well as a physics problem.

    What are the three important elements of the guidelines?

    1. Accountability: Any Indian entity undertaking a planned re-entry, whether within or outside Indian territory, now requires IN-SPACe authorisation.
    2. Foreign operators must route through an Indian entity: Non-Indian entities seeking to undertake planned re-entry over Indian territory must route the activity through an Indian-incorporated entity, such as a subsidiary, joint venture or partnership.
    3. The Indian entity carries the compliance duty: That Indian entity is responsible for complying with Indian laws, regulations and national security requirements.
    4. Why the accountability gap exists: Commercialisation separates ownership from consequence, since the spacecraft may belong to a private company and the effects of its return lie across maritime zones and jurisdictions. India has responded by attaching regulatory responsibility to a re-entering entity before the risk materialises.
    5. Risk must be acceptable: The expected casualty risk must remain below 1 in 10,000, supported by survivability and ground-casualty assessments.
    6. Failure scenarios must be modelled and shared: Operators have to analyse and share failure scenarios, fragmentation patterns, ballistic coefficients, de-orbit plans, flight-path angles and danger zones.
    7. Surviving and hazardous components must be identified: They must identify components likely to survive re-entry, and hazardous systems such as batteries and pressure vessels.
    8. A number makes sustainability measurable: By requiring quantitative studies and attaching a figure to the acceptable risk threshold, the guidelines make sustainability measurable and therefore trackable.
    9. Permissions: IN-SPACe will re-verify the latest re-entry parameters approximately three months before the proposed operation.
    10. A post-launch decision needs six months’ notice: If a planned re-entry is decided upon after launch, the operator must apply at least six months in advance.
    11. Airspace and maritime warnings at 45 days: Operators must obtain an IN-SPACe advisory note to issue warnings to airborne and marine vessels in the re-entry area at least 45 days before the re-entry begins.
    12. A foreign jurisdiction requires that state’s clearance: If a re-entry site falls within the territorial control of a non-Indian state, including its exclusive economic zone, the applicant must submit the relevant clearance or authorisation from that state.
    13. The checkpoints are intervention windows: These checkpoints give the regulator fixed windows and mechanisms to intervene when re-entry parameters change after the mission has launched, or when the risk pattern changes.

    What international framework do the guidelines translate?

    1. The development period: For nearly two decades the international community has developed principles for sustainable space activities.
    2. The two leading instruments: They are the Inter-Agency Space Debris Coordination Committee’s Space Debris Mitigation Guidelines, and the Guidelines for the Long-term Sustainability of Outer Space Activities of the United Nations Committee for the Peaceful Uses of Outer Space.
    3. The treaty foundation: Article IX of the Outer Space Treaty 1967 provides an important foundation for environmental responsibility in the conduct of space activities.
    4. The working definition of sustainability: The UN Guidelines define sustainability as maintaining space activities while preserving the outer space environment for future generations.
    5. The structural weakness of that architecture: Most of the contemporary sustainability architecture works on guidelines and other similar forms of soft law, which operators are not obligated to follow.
    6. How the national regulator closes it: The IN-SPACe guidelines solve this problem for India by tying an operator’s fragmentation analysis and insurance policies to the national regulator, which converts a voluntary standard into a condition of permission.

    How do the guidelines handle liability?

    1. The treaty position on liability: The Space Liability Convention 1972 places absolute liability on a launching state for damage caused by its space object on the surface of the earth, or to aircraft in flight.
    2. The state carries the claim, not the operator: Absolute liability means the launching state answers for the damage regardless of fault, so a private failure becomes a sovereign liability by default.
    3. The guidelines invert that internally: Operators must undertake planned re-entries at their own risk, and they remain liable for third-party damage and claims.
    4. Indemnity to the government: Operators indemnify the Government of India and its agencies for liability incurred under India’s international commitments.
    5. Insurance as the backing: Operators must satisfy the applicable third-party insurance requirements, so the indemnity is funded rather than merely promised.

    Challenges to the IN-SPACe planned re-entry guidelines

    1. The regulator has no statutory backing: IN-SPACe functions as the sector’s regulator without legislative authority, so its guidelines rest on executive policy rather than on an Act. Eg. India has no dedicated space activities legislation, and the Indian Space Policy 2023 is a policy document. Fix. Enact a space activities law placing authorisation, liability and penalties on a statutory footing.
    2. The regulator sits inside the body it regulates: IN-SPACe authorises activities of private companies and government entities including ISRO, and it operates under the Department of Space. Eg. The same department is both the policy custodian and the parent of the entity it must clear. Fix. Place IN-SPACe under an independent appointments and reporting structure, with appeals lying outside the Department of Space.
    3. No appellate route for a refused authorisation: An operator refused authorisation, or held to a risk finding it disputes, has no defined appeal forum. Eg. The guidelines fix a casualty risk threshold without naming any forum before which an operator may contest a risk finding. Fix. Constitute a space disputes appellate tribunal with technical members, on the model used for telecom and electricity regulation.
    4. Verification capacity lags the requirement: A casualty risk below 1 in 10,000 must be independently verifiable, and that requires tracking and modelling capability the regulator does not itself hold. Eg. Debris tracking rests on ISRO’s Project NETRA, which is oriented to collision avoidance rather than to re-entry survivability audit. Fix. Build an independent re-entry analysis cell with access to radar and optical tracking data, empanelling accredited third-party assessors.
    5. Insurance capacity is untested at Indian scale: Third-party space insurance is a thin market, and a small operator may be unable to price cover for a low-probability, high-consequence event. Eg. Indian space startups have grown from a handful to around 200, most of them without balance sheets that carry catastrophic risk. Fix. Create a graded liability cap with a government-backed pool above it, on the model used for civil nuclear liability.

    “[2026] Consider the following statements about involvement of private entities in India’s space programme:

    1. IN-SPACe is an autonomous agency formed to facilitate participation of private entities.

    2. Agnikul Cosmos launched the world’s first flight using 3D-printed rocket engine.

    3. Skyroot Aerospace has developed liquid fuel for GSLV.

    (a) 1 only

    (b) 2 and 3 only

    (c) 1 and 2 only

    (d) 1, 2 and 3

  • How will Gaganyaan’s thermal shield protect the crew?

    Why in the News

    The Gaganyaan crew module will hit the atmosphere at 7,500 to 8,000 metres per second on return, with its exterior reaching 1,800 degrees Celsius while the structure must stay below 150 degrees Celsius. The shield chosen to hold that gap is a sacrificial ablative layer 30 to 35 millimetres thick, a choice driven by the mission’s single use design and India’s own re entry heritage rather than by peak performance.

    What is a thermal protection system?

    1. What it does: A thermal protection system is the outer layer that keeps a re entering vehicle’s structure and interior within survivable temperature while its exterior is exposed to the heat of atmospheric entry.
    2. Why it is needed: Almost all of the crew module’s kinetic energy is dissipated into the atmosphere as heat energy, and the small portion directed back towards the module is still intense enough to melt it.
    3. What it protects: It maintains the module’s structural integrity and keeps the interior within the temperature limit the structure and the crew can tolerate.
    4. How it is classified: Systems are grouped by how they remove heat, into ablative, radiative and heat sink types.

    What is heat flux?

    1. Definition: Heat flux is the rate at which heat energy passes through a unit area of a surface, measured in watts per square metre.
    2. Why it varies on a capsule: It is highest at the point of the vehicle that meets the airflow first, which is why the nose cap carries the most demanding shield material.

    What is a boundary layer?

    1. Definition: The boundary layer is the thin region of gas immediately next to a moving vehicle’s surface, where the flow is slowed by contact with that surface.
    2. Why it matters in ablation: Gases escaping from the decomposing shield thicken and cool this layer, which blocks intense heat from being transferred into the module.

    Why is atmospheric re entry harder than ascent for a crewed mission?

    1. Ascent is controlled and gradual: A rocket accelerates slowly through the atmosphere on the way up specifically to keep the mechanical loads on the vehicle to a minimum.
    2. Re entry cannot be aborted: Once the descent begins there is no provision to abort the mission, so every system must work through to splashdown.
    3. The crew cannot intervene: There is only a limited role for the crew to intervene and correct any system non conformance during descent.
    4. The event is too fast for human correction: Atmospheric descent is incredibly fast and the deceleration forces change constantly, and human response times are simply too high to manually correct a sudden system abnormality.
    5. What follows from this: All systems must therefore be made robust enough to withstand the scorching conditions of re entry on their own, since design margin substitutes for intervention.

    What thermal conditions must the Gaganyaan crew module survive?

    1. Entry velocity: The crew module will hit the atmosphere at a speed of 7,500 to 8,000 metres per second on return from its orbit around the earth.
    2. Energy dissipation: More than 99 per cent of that kinetic energy will be dissipated into the atmosphere as heat energy.
    3. Exterior temperature: The exterior of the module will encounter temperatures as high as 1,800 degrees Celsius in some regions.
    4. Shield thickness: The thermal protection system is just 30 to 35 millimetres thick.
    5. Interior limit: That layer must keep the module’s temperature safely below 150 degrees Celsius while performing the task of maintaining structural integrity.

    How do ablative, radiative and heat sink systems each remove heat?

    1. Ablative: A single use system that removes heat energy by sacrificing its own layers through chemical and physical processes, absorbing extreme quantities of thermal energy and chemically decomposing into a protective layer of solid char and outgassing vapours.
    2. The decomposition physically carries heat away from the module as the material burns off, and the escaping gases create a cooler boundary layer that blocks heat transfer into the module.
    3. Carbon phenolic and silica phenolic are examples of ablative materials.
    4. Radiative: A system that absorbs the extreme heat of re entry and then releases it back into space as electromagnetic radiation, primarily in the infrared spectrum and also as visible light when it is extremely hot.
    5. It remains intact and withstands the heat without melting or degrading, which makes it suited to reusable re entry vehicles.
    6. Heat sink: A system that absorbs heat energy and raises its own temperature without melting or changing phase in any other way.
    7. Copper and aluminium are examples of heat sink materials.

    Why has the Indian Space Research Organisation chosen an ablative shield for the crew module?

    1. It matches the mission’s design philosophy: The Gaganyaan crew module is a single use vehicle, and an ablative system is a single use system, so the shield’s life and the module’s life are the same.
    2. It is proven and robust: The Indian Space Research Organisation (ISRO) has selected it as a proven and highly robust solution rather than the highest performing one available.
    3. It tolerates fluctuating heat loads: Ablative heat shields can easily handle fluctuating heat loads to protect the structure underneath, which matters when the descent profile varies.
    4. Radiative systems are less forgiving: Any design error in a radiative system can quickly cause dangerous overheating, so its margin for error is narrower.
    5. It avoids a maintenance burden: An ablative system withstands an extreme thermal load without requiring complex or delicate surface maintenance between flights.
    6. It avoids the reusable system’s cost structure: By avoiding the expensive manufacturing, specialised inspection and complex installation processes associated with a reusable radiative system, ISRO has taken the safer and more cost effective option.

    Does choosing a single use shield trade away reusability for safety?

    1. What is given up: A sacrificial shield is consumed on every flight, so a new heat shield must be manufactured and installed for each mission rather than inspected and reflown.
    2. The recurring cost consequence: Per flight cost stays flat across a programme instead of falling with flight rate, which is the opposite of the economics a high cadence programme needs.
    3. Why the trade is correct for this mission: Reusability only pays back over a high flight rate, and a first generation crewed programme flying occasional missions never reaches that rate.
    4. Where the trade stops working: A sustained crew rotation programme to an orbital station changes the flight rate, at which point the reusable radiative option becomes the economically relevant one.
    5. The safety side of the trade: The ablative system’s tolerance of fluctuating heat loads and its independence from surface inspection are precisely the properties a programme flying its first crew needs most.

    What does India’s own re entry heritage contribute to the Gaganyaan shield?

    1. The first re entry mission: The Space Capsule Recovery Experiment, India’s maiden re entry mission, used a carbon phenolic ablative to protect the module’s nose cap, where heat flux was the highest.
    2. The crew module demonstration: The Launch Vehicle Mark-3 (LVM3) flew the Crew Module Atmospheric Re-entry Experiment (CARE) in 2014. That flight successfully demonstrated crew module re entry using an ablative thermal protection system.
    3. What that established: The 2014 mission established the foundational technology that is now being used in the Gaganyaan programme, so the shield is an inheritance rather than a new development.
    4. Why heritage reduces risk: Material characterisation, manufacturing process and flight data already exist for the ablative route, which removes the qualification uncertainty a new material class would carry.
    5. The programme position: The Gaganyaan crew module is built on this ablative heritage and on the lessons learned from both earlier missions.

    What does the SpaceX Crew Dragon comparison show about ablative shield design choices?

    1. United States, the Crew Dragon shield: The Crew Dragon capsule of SpaceX uses an ablative material named phenolic impregnated carbon ablator, or PICA, a lightweight carbon fibre matrix filled with a phenolic resin.
    2. The shared design logic: A crewed capsule operator with a very different cost structure has arrived at the same ablative class of solution, which indicates the choice follows from the capsule form rather than from budget constraint.
    3. The design feature that differs: PICA’s lightweight carbon fibre matrix trades density for mass saving, while carbon phenolic of the kind flown on India’s first re entry mission is denser and carries higher heat flux at the nose.
    4. The limit of this comparison: This is the single foreign system named in the evidence here, so it establishes that ablative shielding is the standard choice for crewed capsules, not a ranked comparison of national capsule programmes.

    Challenges to the Gaganyaan thermal protection system

    1. Ground testing cannot reproduce full re entry: No ground facility reproduces the combined velocity, heat flux and duration of an orbital re entry, so qualification relies on partial simulation and analysis. Eg. Arc jet plasma facilities test coupons at representative heat flux but not at the full 7,500 to 8,000 metres per second entry velocity.
    2. Bond line integrity over a curved surface: A 30 to 35 millimetre layer must adhere uniformly over the module’s full curvature, and a bond defect creates a local hot path into the structure. Eg. Shuttle era thermal protection failures originated in localised damage to the protective layer rather than in the material’s bulk performance.
    3. Predicting the recession rate: Ablative design depends on predicting how much material burns off, and an over prediction adds dead mass while an under prediction risks burn through. Eg. Nose cap regions carry the highest heat flux and therefore the largest uncertainty in recession estimates.
    4. Mass penalty on the launch vehicle: A sacrificial shield sized with margin is heavy, and every kilogram of shield reduces the payload the human rated launcher can carry. Eg. The human rated LVM3 has to lift the crew module, service module and shield together to a 400 kilometre orbit.
    5. Manufacturing repeatability: Each mission needs a newly manufactured shield, so process variation between production batches becomes a flight safety variable rather than a quality issue. Eg. Carbon phenolic layup is a manual intensive process where resin content and fibre orientation must be reproduced identically each time.
    6. Recovery environment after splashdown: A charred shield must survive water impact and sea recovery without compromising the crew compartment. Eg. India’s first re entry mission was recovered from the Bay of Bengal, which is the recovery zone the crewed programme also plans to use.
    7. Single point criticality: With no abort provision once descent begins and limited crew intervention, the shield has no backup system to fall back on. Eg. Human response times are too high to correct a sudden thermal abnormality during a descent where deceleration forces change constantly.

    Conclusion

    The Gaganyaan crew module’s protection against a 1,800 degrees Celsius re entry rests on a 30 to 35 millimetre ablative layer that sacrifices itself to carry heat away and hold the structure below 150 degrees Celsius. The choice of an ablative over a radiative system follows from the module’s single use design, its tolerance of fluctuating heat loads and the technology base established by India’s first re entry mission and the 2014 crew module demonstration. The programme’s current status is that the shield is qualified on this heritage, with the first uncrewed test flight launching shortly.

    Human Spaceflight Programme of India

    1. What it is: Gaganyaan is India’s human spaceflight programme, aimed at demonstrating the capability to launch a crew to low earth orbit and return them safely to Indian waters.
    2. Mission profile: The mission is designed to carry a crew of up to three to an orbit of about 400 kilometres for a mission duration of up to three days, followed by splashdown recovery.
    3. The launch vehicle: The launcher is a human rated version of the LVM3, designated the Human rated Launch Vehicle Mark-3 (HLVM3), modified with additional redundancy and a crew escape system.
    4. The orbital module: The crew module and the service module together form the orbital module, with the crew module being the pressurised habitable segment that returns.
    5. Institutional base: The Human Space Flight Centre was established at Bengaluru in 2019 to lead the programme, with the Vikram Sarabhai Space Centre responsible for launch vehicle and re entry systems.
    6. The longer roadmap: India’s stated goals extend to the Bharatiya Antariksh Station by 2035 and a crewed lunar landing by 2040.

    Laws and Treaties Governing Space Activities

    1. Outer Space Treaty, 1967: Makes States internationally responsible for national space activities, whether carried on by governmental or non governmental entities, and bars national appropriation of outer space.
    2. Rescue Agreement, 1968: Obliges States to assist astronauts in distress and to return them and any recovered space objects to the launching authority.
    3. Liability Convention, 1972: Makes a launching State absolutely liable for damage caused by its space object on the surface of the earth or to aircraft in flight.
    4. Registration Convention, 1975: Requires launching States to maintain a national registry of space objects and to furnish details to the United Nations.
    5. Moon Agreement, 1979: Declares the Moon and its resources the common heritage of mankind, and India has signed but not ratified it.
    6. Indian Space Policy, 2023: Defines the roles of ISRO, the Indian National Space Promotion and Authorisation Centre, NewSpace India Limited and non governmental entities in the Indian space ecosystem.
    7. Space Activities Bill, 2017: A draft domestic law to license and regulate private space activity in India, which was circulated for comment and never enacted.
    8. Satellite Communications Policy and spectrum rules: Govern authorisation of satellite services, with spectrum assignment handled under the Telecommunications Act, 2023.

    “[2025] Consider the following space missions:

    I. Axiom-4

    II. SpaDeX

    III. Gaganyaan

    How many of the space missions given above encourage and support microgravity research?

    (a) Only one

    (b) Only two

    (c) All the three

    (d) None